Gedunin modulates cellular growth and apoptosis in glioblastoma cell lines

Michael Stouffer1, Elizabeth Wandling1, Lindsay Dickson1

  • 1Department of Pharmaceutical Sciences, Cedarville University School of Pharmacy, Cedarville University, Cedarville, Ohio, USA.

Abstract

Insights

Gedunin, a natural product, effectively suppressed glioblastoma cell growth and induced apoptosis by inhibiting heat shock protein 90 (HSP90) and cancer survival proteins.

Area of Science:

  • Oncology
  • Molecular Biology
  • Natural Products Chemistry

Background:

  • Glioblastomas are aggressive brain tumors with limited treatment options due to drug resistance.
  • Conventional therapies like surgery, radiotherapy, and temozolomide often fail.
  • Gedunin, a natural product and heat shock protein 90 (HSP90) inhibitor, shows potential against various diseases.

Purpose of the Study:

  • To investigate the effects of gedunin on glioblastoma cell biological and signaling mechanisms.
  • To determine how gedunin influences glioblastoma cell proliferation and apoptosis.
  • To explore gedunin's potential as a novel therapeutic agent for glioblastoma.

Main Methods:

  • Cell viability assessed via MTT, cell counts, and wound healing assays.
  • Gedunin's impact on glioma cells confirmed with LDH and colony formation assays.
  • Apoptotic and survival signaling pathways analyzed using Western blot and flow cytometry.

Main Results:

  • Gedunin significantly reduced glioblastoma cell viability and inhibited wound healing.
  • Treatment induced apoptosis through poly ADP-ribose polymerase cleavage, caspase activation, and BCL-xL downregulation.
  • Gedunin suppressed cancer cell growth and HSP client proteins, including EGFR and mTOR/Akt/NF-κB pathways.

Conclusions:

  • Gedunin exhibits in vitro anticancer activity against glioblastoma cells.
  • The compound effectively downregulates key cancer survival proteins.
  • Gedunin demonstrates potential as a therapeutic agent for glioblastoma treatment.